Herein, we summarize strategies and preventive measure inthe management of uveitis patients during COVID-19.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Since several cases of pneumonia of unknown microbial origin that were detected at Wuhan City, China in late December 2019, entire countriesare under lockdown to limit the spread of the virus.
📊
Key Findings & Data:During this emergency state, accessibility to healthcare services is an increasing challenge.Uveitis population is one of the vulnerable groups which need constant follow-up and guidance because the nature course of their disease.
💡
Conclusion & Impact:Herein, we summarize strategies and preventive measure inthe management of uveitis patients during COVID-19.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters
Özet
Since several cases of pneumonia of unknown microbial origin that were detected at Wuhan City, China in late December 2019, entire countriesare under lockdown to limit the spread of the virus. During this emergency state, accessibility to healthcare services is an increasing challenge.Uveitis population is one of the vulnerable groups which need constant follow-up and guidance because the nature course of their disease. It hasbeen particularly concerning for the patients taking immunomodulatory treatment. Herein, we summarize strategies and preventive measure inthe management of uveitis patients during COVID-19.
🔖
Cite This Article
HASANREİSOĞLU, M., HASANREİSOĞLU, B. (2020). COVID-19 Pandemia - Uveitis Specialist Perspective. Retina-Vitreus, Cilt: 29 - Sayı: 2, 166–169. https://ajindex.com/articles/340336
References (15)
Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020
World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report Available from: https://wwwwhoint/docs/default-source/coronaviruse/ s i t u a t i o n - r e p o r t s / 2 0 2 0 0 3 11 - s i t r e p - 5 1 - c o v i d - 19pdf?sfvrsn=1ba62e57_10 2020
Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020;92(4):401-2
Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva- O'Callaghan A, Pardos-Gea J, Quintana A, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020:102569
IUSG. Evolving Consensus Experience of the IUSG with uveitis in the time of COVID-19 infection. https:// wwwiusgnet/uploads/images/IUSG%20Library/001- Consensus-Experience-Documentpdf. 2020
Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. Clin Infect Dis. 2020
Ye Z, Wang Y, Colunga-Lozano LE, Prasad M, Tangamornsuksan W, Rochwerg B, et al. Effi cacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, infl uenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ. 2020
Sanchez-Pernaute O, Romero-Bueno FI, Selva-O'Callaghan A. Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia. Reumatol Clin. 2020
Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, et al. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 2005;75(2):185-94
Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, et al. Modulation of TNF-alphaconverting enzyme by the